Information Provided By:
Fly News Breaks for March 23, 2017
SNY, FLXN
Mar 23, 2017 | 14:27 EDT
Cantor Fitzgerald analyst Chiara Russo noted that FiercePharma reported that Sanofi (SNY) is in talks to acquire Flexion (FLXN) at a price in the "mid-30s" per share, adding that she sees such a price as "being a little low for a strategic buyer" given Zilretta's opportunity to take significant market share, if approved. Russo has an Overweight rating and $34 price target on Flexion shares.
News For FLXN;SNY From the Last 2 Days
SNY
Mar 27, 2024 | 06:16 EDT
Wells Fargo analyst Derek Archila raised the firm's price target on Annexon (ANNX) to $12 from $11 and keeps an Overweight rating on the shares. The firm believes the risk/reward remains favorable ahead of ANX005's Phase 3 data in GBS. Additionally, updates for ANX007 at ARVO, Phase 3 GBS data at PNS and read through from Sanofi's (SNY's) riliprubart in CIDP at AAN, all could offer upside for shares, Wells adds.